Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Condition: High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
MeSH terms: Glioblastoma; Glioma; Recurrence
Intervention: nab-sirolimus; nab-sirolimus + temozolomide; nab-sirolimus + bevacizumab; nab-sirolimus + lomustine; nab-sirolimus + marizomib (MRZ); nab-sirolimus + temozolomide + radiotherapy
Intervention description: nab-sirolimus, single agent; temozolomide, combination; bevacizumab, combination; lomustine, combination; marizomib (MRZ), combination; temozolomide + radiotherapy, combination
Intervention MeSH terms: Sirolimus; Bevacizumab; Temozolomide; Temsirolimus; Lomustine; MTOR Inhibitors
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Masking: None (Open Label)
Enrollment: 62.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma
      following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was
      administered as single agent or in combination therapies.
    

Eligibility criteria:

        Inclusion Criteria Specific for Arm A

          1. All subjects must have histologic evidence of high grade glioma (World Health
             Organization [WHO] grade 3 or grade 4) and radiographic evidence of recurrence or
             disease progression (defined as either a greater than 25% increase in the largest
             bi-dimensional product of enhancement, a new enhancing lesion, or a significant
             increase in T2 FLAIR). Subjects must have at least 1 measurable lesion by RANO
             criteria (≥ 10 mm in 2 perpendicular diameters).

          2. Patients must have previously failed a treatment regimen, including radiation and/or
             chemotherapy.

          3. No prior treatment with mTOR inhibitors.

          4. No prior treatment with temozolomide for the treatment of recurrent glioma for
             patients entering the ABI-009 + temozolomide cohort.

          5. No prior treatment with bevacizumab or any other anti-angiogenic agents, including
             sorafenib, sunitinib, axitinib, pazopanib, or cilengitide for the ABI-009 +
             bevacizumab arm.

          6. No prior treatment with lomustine for the ABI-009 + lomustine arm.

          7. No prior treatment with marizomib or any other proteasome inhibitors, including
             bortezomib, carfilzomib, or ixazomib, for patients entering the ABI-009 + marizomib
             cohort.

          8. At least 4 weeks from surgical resection and at least 12 weeks from the end of
             radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor
             biopsy or new lesion outside of radiation field, or if there are two MRIs confirming
             progressive disease that are approximately 4 weeks apart.

        Inclusion Criteria Specific for Arm B

          1. Histologically confirmed newly diagnosed glioblastoma.

          2. Patients must have had surgery and can have either non-measurable disease or a
             measurable post-contrast lesion after surgery detected by MRI.

          3. No prior treatment with mTOR inhibitors, and no prior local or systemic therapy for
             GBM.

        Exclusion Criteria Common for Both Arms A and B

        A patient will not be eligible for inclusion in this study if any of the following criteria
        apply:

          1. Co-medication or concomitant therapy that may interfere with study results, including
             anti-coagulants and enzyme-inducing anti-epileptic drugs (EIAEDs).

          2. History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.

          3. Pregnant or breast feeding.

          4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring IV antibiotics & psychiatric illness/social situations that would
             limit compliance with study requirements, or disorders associated with significant
             immunocompromised state.

          5. Active gastrointestinal bleeding.

          6. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood
             pressure ≥90 mm Hg.

          7. Patients with history of intestinal perforations, fistula, hemorrhages and/or
             hemoptysis ≤6 months prior to first study treatment.

          8. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.

          9. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary
             hypertension.

         10. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to
             receiving the first dose of ABI-009.

         11. Known other previous/current malignancy requiring treatment within ≤ 3 years except
             for limited disease treated with curative intent, such as in situ prostate cancer,
             intracapsular renal cancer, cervical carcinoma in situ, squamous or basal cell skin
             carcinoma, and superficial bladder carcinoma.

         12. Any comorbid condition that restricts the use of study drug and confounds the ability
             to interpret data from the study as judged by the Investigator or Medical Monitor.

         13. Known Human Immunodeficiency Virus (HIV), or active Hepatitis B or Hepatitis C.